Myriad Genetics buys Rules-Based Medicine

Friday, April 29, 2011 01:20 PM

A Utah-based biotech company, Myriad Genetics, will buy Rules-Based Medicine for $80 million, according to The Salt Lake Tribune.

Myriad reports that the acquisition expands its research portfolio to include biomarkers for new disease areas such as psychiatric disorders, infections diseases and inflammatory diseases.

Rules-Based Medicine works with more than 20 pharmaceutical and biotech partners in developing new biomarkers and has operations in Texas, N.Y., and Germany.

It will operate as a wholly owned subsidiary of Myriad and be called Myriad RBM.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs